United Therapeutics slips on further delays for RemoSynch

United Therapeutics Corp. (NASDAQ:UTHR) fell $12.79 to $122.17, losing $553 million in market cap, after reporting during its 4Q17 earnings call Wednesday that RemoSynch, the implantable drug infusion system for Remodulin treprostinil, will launch "within the next 12 months." Investors had anticipated the product's launch as early as April.

RemoSynch's launch will most likely fall after the expected June launch of a Remodulin generic from the Sandoz Ltd. unit of Novartis AG (NYSE:NVS; SIX:NOVN)...